Biblio

Author Title [ Type

] Year

Filters: Author is Michallet, Mauricette [Clear All Filters]

Journal Article

Michallet M, Sobh M, Serrier C, Morisset S, Labussière H, Ducastelle S, Barraco F, Gilis L, Thomas X, Nicolini FE. Allogeneic hematopoietic stem cell transplantation for hematological malignancies from mismatched 9/10 HLA unrelated donors: Comparison with transplantations from 10/10 unrelated donors and HLA identical siblings. Leuk Lymphoma. 2014:1-16.

Nagler A, Rocha V, Labopin M, Unal A, Ben Othman T, Campos A, Volin L, Poire X, Aljurf M, Masszi T, et al. Allogeneic Hematopoietic Stem-Cell Transplantation for Acute Myeloid Leukemia in Remission: Comparison of Intravenous Busulfan Plus Cyclophosphamide (Cy) Versus Total-Body Irradiation Plus Cy As Conditioning Regimen--A Report From the Acute Leukemia Worki. J Clin Oncol. 2013.

Bertoli S, Paubelle E, Bérard E, Saland E, Thomas X, Tavitian S, Larcher M-V, Vergez F, Sarry A, Huguet F, et al. Ferritin heavy/light chain (FTH1/FTL) expression, serum ferritin levels and their functional as well as prognostic roles in acute myeloid leukemia. Eur J Haematol. 2018.

Beaussant Y, Daguindau E, Pugin A, Mohty M, Avet-Loiseau H, Roos-Weil D, Michallet M, Chevalier P, Raus N, El-Cheikh J, et al. Hematopoietic stem cell transplantation in multiple myeloma. A retrospective study of the Société Française de Greffe de Moelle et de Thérapie Cellulaire (SFGM-TC). Biol Blood Marrow Transplant. 2015.

Schlemmer F, Chevret S, Lorillon G, De Bazelaire C, de Latour RPeffault, Meignin V, Michallet M, Hermet E, Wyplosz B, Houdouin V, et al. Late-onset noninfectious interstitial lung disease after allogeneic hematopoietic stem cell transplantation. Respir Med. 2014.

Plesa A, Chelghoum Y, Mattei E, Labussière H, Elhamri M, Cannas G, Morisset S, Tagoug I, Michallet M, Dumontet C, et al. Mobilization of CD34(+)CD38(-) hematopoietic stem cells after priming in acute myeloid leukemia. World J Stem Cells. 2013;5(4):196-204.

Hayashi H, Volt F, Sanz J, Petersen E, Dhedin N, Hough R, Milpied N, Angelucci E, Yakoub-Agha I, Michallet M, et al. Myeloablative unrelated cord blood transplantation in adolescents and young adults with acute leukemia. Biol Blood Marrow Transplant. 2019.

Poire X, Labopin M, Cornelissen JJ, Volin L, Espiga CRichard, J Veelken H, Milpied N, Cahn J-Y, Yacoub-Agha I, van Imhoff GW, et al. Outcome of conditioning intensity in acute myeloid leukemia with monosomal karyotype in patients over 45 year-old: A study from the Acute Leukemia Working Party (ALWP) of the European group of Blood and Marrow Transplantation (EBMT). Am J Hematol. 2015.

Baron F, Ruggeri A, Peczynski C, Labopin M, Bourhis J-H, Michallet M, Chevallier P, Sanz J, Forcade E, Saccardi R, et al. Outcomes of graft failure after umbilical cord blood transplantation in acute leukemia: a study from Eurocord and the Acute Leukemia Working Party of the EBMT. Bone Marrow Transplant. 2023.

Fenwarth L, Thomas X, de Botton S, Duployez N, Bourhis J-H, Lesieur A, Fortin G, Meslin P-A, Yakoub-Agha I, Sujobert P, et al. A Personalized Approach to Guide Allogeneic Stem Cell Transplantation in Younger Adults with Acute Myeloid Leukemia. Blood. 2020.

Michallet M, Sobh M, Labussière H, Lombard C, Barraco F, El-Hamri M, Thomas X, Chapuis-Cellier C, Nicolini FE. Potential anti-leukemic activity of iron chelation after allogeneic hematopoietic stem cell transplantation in patients with acute myeloid leukemia. Leuk Lymphoma. 2016:1-4.

Sheth V, Volt F, Sanz J, Clement L, Cornelissen J, Blaise D, Sierra J, Michallet M, Saccardi R, Rocha V, et al. Reduced-intensity versus myeloablative conditioning in cord blood transplantation for AML (40-60 years) across highly mismatched HLA barriers - On behalf of Eurocord and the Cellular Therapy & Immunobiology Working Party (CTIWP) of EBMT. Biol Blood Marrow Transplant. 2020.

Frobert E, Burrel S, Ducastelle-Lepretre S, Billaud G, Ader F, Casalegno J-S, Nave V, Boutolleau D, Michallet M, Lina B, et al. Resistance of herpes simplex viruses to acyclovir: an update from a ten-year survey in France. Antiviral Res. 2014.

Chevallier P, Labopin M, Socié G, Tabrizi R, Furst S, Lioure B, Guillaume T, Delaunay J, de la Tour RPeffault, Vigouroux S, et al. Results from a clofarabine-busulfan containing reduced-toxicity conditioning regimen prior to allogeneic stem cell transplantation: the phase II prospective CLORIC trial. Haematologica. 2014.

Belkacemi Y, Labopin M, Giebel S, Gorin NClaude, Loganadane G, Miszczyk L, Michallet M, Socié G, Schaap NPm, Cornelissen JJ, et al. Single Dose Daily Fractionated Is Not Inferior To Twice A Day Fractionated Total Body Irradiation Prior To Allogeneic Stem Cell Transplantation For Acute Leukemia: A Useful Practice Simplification Resulting From The Sarasin Study. Int J Radiat Oncol Biol Phys. 2018.

Pan H, Gazarian A, Dubernard J-M, Belot A, Michallet M-C, Michallet M. Transplant Tolerance Induction in Newborn Infants: Mechanisms, Advantages, and Potential Strategies. Front Immunol. 2016;7:116.

Beelen DWilhelm, Trenschel R, Stelljes M, Groth C, Masszi T, Reményi P, Wagner-Drouet E-M, Hauptrock B, Dreger P, Luft T, et al. Treosulfan or busulfan plus fludarabine as conditioning treatment before allogeneic haemopoietic stem cell transplantation for older patients with acute myeloid leukaemia or myelodysplastic syndrome (MC-FludT.14/L): a randomised, non-inferiority, phase 3 . Lancet Haematol. 2019.

Ruggeri A, Battipaglia G, Labopin M, Ehninger G, Beelen D, Tischer J, Ganser A, Schwerdtfeger R, Glass B, Finke J, et al. Unrelated donor versus matched sibling donor in adults with acute myeloid leukemia in first relapse: an ALWP-EBMT study. J Hematol Oncol. 2016;9(1):89.